A5039662468- Immune cells in cancer
- Glioma Diagnosis and Treatment
- Nanoparticle-Based Drug Delivery
- S100 Proteins and Annexins
- Neuroinflammation and Neurodegeneration Mechanisms
- Brain Metastases and Treatment
- Phagocytosis and Immune Regulation
- Nanoplatforms for cancer theranostics
- Advanced Radiotherapy Techniques
- Medical Imaging Techniques and Applications
- Radiomics and Machine Learning in Medical Imaging
- Radiation Therapy and Dosimetry
- CAR-T cell therapy research
- Radiation Effects and Dosimetry
- Radiopharmaceutical Chemistry and Applications
- Cancer Research and Treatments
Athinoula A. Martinos Center for Biomedical Imaging
2018-2023
Massachusetts General Hospital
2017-2023
We evaluated the efficacy of bavituximab-a mAb with anti-angiogenic and immunomodulatory properties-in newly diagnosed patients glioblastoma (GBM) who also received radiotherapy temozolomide. Perfusion MRI myeloid-related gene transcription inflammatory infiltrates in pre-and post-treatment tumor specimens were studied to evaluate on-target effects (NCT03139916).Thirty-three adults IDH--wild-type GBM 6 weeks concurrent chemoradiotherapy, followed by cycles temozolomide (C1-C6). Bavituximab...
<div>Abstract<p>Purpose: We evaluated the efficacy of bavituximab – a monoclonal antibody with anti-angiogenic and immunomodulatory properties in newly diagnosed glioblastoma (GBM) patients who also received radiation temozolomide. Perfusion MRI myeloid-related gene transcription inflammatory infiltrates pre-and post-treatment tumor specimens were studied to evaluate on-target effects (NCT03139916). Patients Methods: Thirty-three adults...
<p>Supplemental Data</p>
<p>Supplemental Data</p>
<p>Supplemental Data</p>
<p>Supplemental Data</p>
<div>AbstractPurpose:<p>We evaluated the efficacy of bavituximab—a mAb with anti-angiogenic and immunomodulatory properties—in newly diagnosed patients glioblastoma (GBM) who also received radiotherapy temozolomide. Perfusion MRI myeloid-related gene transcription inflammatory infiltrates in pre-and post-treatment tumor specimens were studied to evaluate on-target effects (NCT03139916).</p>Experimental design:<p>Thirty-three adults <i>IDH</i>--wild-type...
<div>Abstract<p>Purpose: We evaluated the efficacy of bavituximab – a monoclonal antibody with anti-angiogenic and immunomodulatory properties in newly diagnosed glioblastoma (GBM) patients who also received radiation temozolomide. Perfusion MRI myeloid-related gene transcription inflammatory infiltrates pre-and post-treatment tumor specimens were studied to evaluate on-target effects (NCT03139916). Patients Methods: Thirty-three adults...
<p>Supplemental Data</p>
<div>AbstractPurpose:<p>We evaluated the efficacy of bavituximab—a mAb with anti-angiogenic and immunomodulatory properties—in newly diagnosed patients glioblastoma (GBM) who also received radiotherapy temozolomide. Perfusion MRI myeloid-related gene transcription inflammatory infiltrates in pre-and post-treatment tumor specimens were studied to evaluate on-target effects (NCT03139916).</p>Patients Methods:<p>Thirty-three adults <i>IDH</i>--wild-type GBM 6...
<p>Supplemental Data</p>
Increases in contrast enhancement due to treatment related inflammation creates a significant clinical conundrum for neuro-oncologists. Our goal was use simultaneous PBR28 PET-MRI measure TSPO, marker of microglia activation as well glioma cells, patients with glioblastoma (GBM). In this pilot study, who received immunotherapy recurrent GBM or newly diagnosed suspected pseudoprogression after completion temozolomide+radiation were recruited at single institution between 2014-2017....
Immunotherapy has been effective therapy for brain metastases (BM) from melanoma and lung cancer, prompting interest in using PD-1 targeting drugs more patients with BM. However, accurately assessing response undergoing immunotherapy continues to be a challenge. Thus, we prospectively evaluated radiographic characteristics changes during immunotherapy. As part of an ongoing Phase 2 study pembrolizumab untreated or progressive, previously treated BM any histology, underwent advanced MRI that...
Glioblastoma and tumor endothelial cells express phosphatidylserine, a highly immunosuppressive membrane phospholipid. Bavituximab chimeric monoclonal antibody binds to 2-glycoprotein 1 (2-GP1) form complex of 2-GP1 with resulting in immune activation against anti-angiogenic effects. Phase I/II trials other solid cancers have demonstrated response rates up 85% when bavituximab was given cytotoxic chemotherapy. Pre-clinical data glioblastoma models suggested synergistic effects...
May 5, 2019April 9, 2019Free AccessMRI changes in patients with newly diagnosed glioblastoma treated as part of a Phase II trial bavituximab, radiation, and temozolomide (P1.6-003)Ina Ly, Jonathan Cardona, Andrew Beers, Ken Chang, James Brown, David Reardon, Isabel Arrillaga-Romany, … Show All , Jorg Dietrich, Deborah Forst, Eudocia Lee, Justin Jordan, Lakshmi Nayak, Patrick Wen, Tracy Batchelor, William Curry, Jayashree Kalpathy-Cramer, Elizabeth Gerstner FewerAuthors Info &...
2546 Background: Glioblastoma and tumor endothelial cells express phosphatidylserine (PS), a highly immunosuppressive membrane phospholipid. Bavituximab – chimeric monoclonal antibody binds to β2-glycoprotein 1 (β2-GP1) form complex of β2-GP1 with PS, resulting in immune activation against anti-angiogenic effects. Phase I/II trials other solid cancers demonstrated response rates up 75% when bavituximab was given cytotoxic chemotherapy. Pre-clinical data glioblastoma models suggested...
Abstract Immune checkpoint inhibitors (ICI) have recently been shown to be effective for brain metastases (BM) in melanoma and lung cancer. However, accurately assessing intracranial response patients undergoing ICI is a challenge, as current measures cannot reliably distinguish pseudoprogression from true tumor progression. To identify potential biomarkers of response, we analyzed standard post-contrast dynamic susceptibility contrast MRI characteristic vascular signatures part an ongoing...